AIM AIM ImmunoTech

AIM ImmunoTech CEO to Participate in Virtual Panel Presentation at the 23rd Annual BioFlorida Conference on October 29th

AIM ImmunoTech CEO to Participate in Virtual Panel Presentation at the 23rd Annual BioFlorida Conference on October 29th

OCALA, Fla. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to participate in a virtual panel titled, “COVID-19: Progress on Treatments & Prevention” on Thursday, October 29, at 10:05 A.M. Eastern Time at the 23rd Annual BioFlorida Conference. The presentation will be webcast live on the conference event platform, which can be accessed .

The BioFlorida Conference 2020 will feature global experts in keynote and breakout sessions addressing the latest trends in BioPharma, MedTech, HealthIT and COVID-19. Informative programs will cover current science advancements, business and public policy, as well as showcase Florida’s achievements and innovation.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus. For more information on AIM ImmunoTech, please visit .

Contacts:

Crescendo Communications, LLC

Phone: 212-671-1021

Email: 

AIM ImmunoTech Inc

Phone: 800-778-4042

Email: 

EN
22/10/2020

Underlying

AIMAIM ImmunoTech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM ImmunoTech

 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Publication of Journal Article On the Positiv...

AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth New peer-reviewed article appears in the Journal for ImmunoTherapy of Cancer OCALA, Fla., Sept. 22, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published a new peer-reviewed article providing evidence of a positive combination effect of AIM’s drug Ampligen and interferon-alpha on tumor growth and subsequent subject survival. The paper concluded that the ability...

September 22, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen ...

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation now available Ampligen has demonstrated data-driven promise in Progression-Free Survival and Overall Survival in both the DURIPANC clinical trial and an Early Access Program OCALA, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- (NYSE American...

September 4, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Release of the Next CEO Corner Segment Tom Equels, CEO of AIM ImmunoTech provides a corporate update and reiterates focus on driving Ampligen forward in pancreatic cancer OCALA, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced the next segment has been published on the Company’s website. In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels provides a “state of the union” corporate update and discusses the recent scientific progress made with lead product candidate, Ampligen. ...

August 21, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provi...

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates promising signs of both no significant toxicity and superior PFS and OS Bolstered cash position provides runway to fund operations for approximately 12 months OCALA, Fla., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or...

August 15, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech to Present at the Webull Financial Corporate Connect We...

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech Live video webcast on Wednesday, August 20th at 2:40 PM ET   OCALA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Wednesday, August 20, 2025 at 2:40 PM ET Presenter: Registration Link: About Webull Financial Webull Financial is a leading online brokerage platform committed t...

August 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch